이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Opthea 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Fred Guerard

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

CEO

Fred Guerard (51 yo)

less than a year

테뉴어

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Megan Baldwin	Founder	no data	US$1.57m	0.018% $ 67.4k
Judith Robertson	Chief Commercial Officer	2.5yrs	US$856.83k	데이터 없음
Karen Adams	VP of Finance & Company Secretary	3.1yrs	US$507.60k	데이터 없음
Frederic Guerard	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Peter Lang	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Sarika Gulhar	Executive Director of Human Resources	1.5yrs	데이터 없음	데이터 없음
Michael Gerometta	Head of Chemistry	15.6yrs	US$197.04k	데이터 없음
Bruno Gagnon	Senior Vice President of Global Clinical Operations	1.8yrs	데이터 없음	데이터 없음
Kenneth Sall	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	데이터 없음
Julie Clark	Senior Vice President of Clinical Development	less than a year	데이터 없음	데이터 없음
Arshad Khanani	Chief Medical Advisor	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: OPT 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Megan Baldwin	Founder	no data	US$1.57m	0.018% $ 67.4k
Jeremy Levin	Chairperson	3.8yrs	US$425.47k	0.0029% $ 10.9k
Jason Slakter	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Quinton Oswald	Independence Non-Executive Director	2.3yrs	US$202.36k	데이터 없음
Julia Haller	Independent Non-Executive Director	3.1yrs	US$327.41k	데이터 없음
Lawrence Gozlan	Independent Non-Executive Director	4yrs	US$724.31k	0.17% $ 647.7k
Sujal Shah	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Anshul Thakral	Non-Executive Director	1.1yrs	US$3.16k	데이터 없음
Charles Wykoff	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Susan Orr	Independent Non-Executive Director	2.3yrs	US$206.20k	데이터 없음
Tim Jackson	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: OPT 의 이사회는 경험(평균 재직 기간 2.2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Opthea 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Recent updates

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Price target decreased to AU$4.24

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Independent Non-Executive Director exercised options to buy AU$1.1m worth of stock.

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD